<DOC>
	<DOCNO>NCT00711503</DOCNO>
	<brief_summary>A draw trial effect Interleukin-1 Receptor Antagonist ( anakinra , Kineret® ) insulin production patient new onset Type 1 diabetes . Kineret® already use treatment patient suffer rheumatoid arthritis preclinical study suggest may also useful patient Type 1 diabetes . The active substance Kineret interleukin-1 receptor antagonist , blocker immune-signal molecule name interleukin-1 . The trial blind randomised trial , patient allocate receive active drug ( Kineret® ) placebo ( saline ) . The hypothesis anti-IL-1 treatment add-on therapy conventional insulin therapy preserve enhance beta-cell function .</brief_summary>
	<brief_title>Anti-Interleukin-1 Diabetes Action</brief_title>
	<detailed_description>Objectives : The aim Anti-Interleukin-1 Diabetes Action trial ( AIDA ) study test feasibility , safety/tolerability potential efficacy anti-IL-1 therapy maintain enhance beta-cell function people new onset Type 1 diabetes . Trial Design : A randomized , placebo control , double mask , parallel group , multicentre trial IL-1 antagonism subject newly-diagnosed Type 1 diabetes . Patients instruct inject 100 mg human recombinant interleukin-1 receptor antagonist ( anakinra , Kineret® , Amgen , CA ) placebo s.c. daily 2 year . Endpoints evaluate every three month , interim analysis 6 month . Trial population : The design two-stage phase 2a study address feasibility , safety/tolerability potential efficacy . In first phase 80 patient 18 35 year age new on-set Type 1 diabetes randomize anakinra placebo , endpoint analyze interim analysis 6 month independent data safety monitor board ( DSMB ) . A futility analysis perform time point prevent continuation trial show likelihood demonstrate efficacy . In event trial show promise efficacy consider power first phase base conditional analysis DSMB recommend prolongation study recruitment ensure adequate power , additional funding provide . Methods intervention : The patient instructed administer anti-IL-1 therapy form recombinant human non-glycosylated interleukin-1 receptor antagonist ( anakinra ) dose 100 mg daily placebo subcutaneous injection time-point morning . Primary secondary endpoint safety parameter investigate 1 month every 3 month . Safety : Anakinra FDA approve indication rheumatoid arthritis acceptable risk / benefit profile indication , 100.000 patient treat . Most common ad-verse event include mild transient local injection reaction 20-50 % subject treat Anakinra . Consistent mechanism action , anakinra reduces WBC/ANC 2.4 % patient may increase risk infection . Accordingly , treatment anakinra initiate patient active infection . Safety monitor physical exam blood urine test .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Type 1 diabetes diagnose accord WHO 1999 criterion Positive GAD autoantibodies Age 1835 yr onset diabetes Time first symptoms diabetes &lt; 12 week Peak Cpeptide equal 200 pM standardize mixed meal test ( Boost ) test carry subject metabolically stable , i.e . resolution polyuria , polydypsia ketoacidosis . Severe liver renal disease ( creatinine &gt; 100 μmol/L , ASAT/ALAT &gt; 2* ULN , alkaline phosphatase &gt; 2 * ULN ) History heart disease , sign cardiac failure abnormal ECG Present previous malignancy Pregnancy failure fertile female comply contraceptional planning , breastfeed . ( Safe contraceptive method include birth control pill , IUD , gestagen implant ) . Plans pregnancy within 2 year . Participation clinical intervention study Antiinflammatory therapy ( except aspirin £ 100 mg/d ) Active infection ( CRP &gt; 30 ) , history recurrent infection predisposition infection Neutropenia : ANC &lt; 1.5*109/L , anaemia : Haemoglobin &lt; 8.0 g/dL Immunesuppressive treatment immunedeficiency Presence diagnosis late diabetic complication Concurrent vaccination live vaccine . Known need live vaccination within 2 year . Use Etanercept within 6 month screen doubleblinded study period Hypersensitivity E. coliderived protein , anakinra component product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>endogenous insulin production</keyword>
	<keyword>C-peptide level</keyword>
	<keyword>insulin requirement</keyword>
</DOC>